Tom Ross, executive vice-president for global sales, said: "Researchers in Asia continue to play an increasingly important role in the discovery and development of new biologics and small molecule drugs, and thus Asia is a focal market for MaxCyte's instruments business."
Kiko Tech Co, established in 1974, will serve throughout Japan as the authorized distributor for the MaxCyte transfection systems for drug discovery and biomanufacturing.
Bio Laboratories Pte Ltd will be the distributor of the systems in Singapore.
Ross added: "Many leading Asian pharmaceutical companies already use the MaxCyte STX Scalable Transfection System.
"In addition, we are adding new staff, including a senior-level manager, to support our business in Asia."
The MaxCyte GT Flow Transfection System, the MaxCyte STX Scalable Transfection System, and the MaxCyte VLX Large Scale Transfection System enable the rapid development of transfected cells for a broad array of applications.
MaxCyte is also developing CARMA - its proprietary platform in immuno-oncology.
Shares eased 2.22% to 82.62p.